Top Industry News

Gilead Sciences has agreed to acquire Tubulis, a Munich, Germany-based clinical-stage bio/pharmaceutical company developing antibody-drug conjugates (ADCs), in a deal worth up to $5 billion ($3.15 billion upfront and $1.85 billion in milestone payments).  The acquisition will expand Gilead’s ADC capabilities by adding…

Neurocrine Biosciences, a San Diego, California-based bio/pharmaceutical company, has agreed to acquire Soleno Therapeutics, a Redwood City, California-based bio/pharmaceutical company, for $2.9 billion.  The acquisition will add Vykat XR (diazoxide choline), a therapy to treat hyperphagia (extreme, insatiable…

The US Environmental Protection Agency (EPA) Administrator Lee Zeldin and US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced last week (April 2, 20269 coordinated…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Shionogi and Gilead Sciences. Highlights below.   For the latest news roundup on small and Emerging Pharma companies, see Biotech…

The latest from small and Emerging Pharma companies featuring Jeito Capital, Collegium Pharmaceutical, Corium Therapeutics, Sidewinder Therapeutics and Stipple Bio.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. …

Eli Lilly and Company has agreed to acquire Centessa Pharmaceuticals, a clinical-stage bio/pharmaceutical company focused on excessive daytime sleepiness and other neurological conditions, in a deal worth up to $7.8 billion ($6.3 billion upfront and $1.5 billion in…

Merck & Co. has agreed to acquire Terns Pharmaceuticals, a clinical-stage bio/pharmaceutical company focused on oncology, for $6.7 billion.  Terns’ lead candidate, TERN-701, is an investigational oral drug for treating chronic phase chronic myeloid leukemia (CML). Specifically it…

UCB, a Brussels, Belgium-based bio/pharmaceutical company, has selected Rowen, Gwinnett County, Georgia, as the location for its new US biologics manufacturing facility. UCB announced plans to invest in the new facility in June 2025.  Spanning approximately 460,000 square…

Biogen has agreed to acquire Apellis Pharmaceuticals, a commercial-stage bio/pharmaceutical company, for $5.6 billion to expand its position in immunology, rare diseases, and nephrology (i.e., kidney disease).    The acquisition brings two commercial immunology products to Biogen: Empaveli (pegcetacoplan), FDA-approved in three indications, including two…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Novartis, Gilead Sciences, Otsuka, Merck & Co., Roche, Recordati, and Takeda. Highlights below.   M&A News * Novartis To Acquire Synnovation’s Oncology Drug in $3-Bn Deal * Gilead To Acquire Ouro Medicines…